GSK plans to sell two vaccine products to Pfizer due to antitrust suspicion
-
Last Update: 2015-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: DXY 2015-06-24 GlaxoSmithKline has agreed to sell two meningitis vaccines to Pfizer, addressing the recent antitrust concerns arising from the acquisition of Novartis vaccine business On June 22nd the British drugmaker said it had sold its nimenrix and mencevax products to Pfizer's Irish arm for a total of 115 million euros ($131 million), including some late payments GlaxoSmithKline agreed to sell two older vaccine products outside the US, with total sales of £ 340 million (US $540 million) last year, in response to questions raised by the European Commission and other antitrust regulators The meningitis vaccine was challenged by antitrust because GlaxoSmithKline acquired two competing products from Novartis, known as menveo and bexsero The deal with Pfizer is expected to be completed by the end of this year.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
